NCT03138629No Longer Available不适用
Expanded Access to VAL-083
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to VAL-083 (dianhydrogalactitol) prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has relapsed/refractory disease and exhausted all standard treatments.
排除标准
- •Patient is eligible for a VAL-083 clinical trial.
- •Patient has previously received VAL-083 for the same disease.
研究者
相似试验
Available
不适用
Expanded Access to VenetoclaxChronic Lymphocytic Leukemia (CLL)Acute Myeloid Leukemia (AML)Non-Hodgkin's LymphomaAcute Lymphoblastic Leukemia (ALL)Plasma Cell LeukemiaMultiple MyelomaAmyloidosisNCT03123029AbbVie
No Longer Available
不适用
Expanded Access to VeliparibSolid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically SoundTriple Negative Breast Cancer (TNBC)High Grade Serous Ovarian CancerPatients Requiring Veliparib Suspension FormulationNCT03123211AbbVie
No Longer Available
不适用
Expanded Access to ABBV-8E12Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)NCT03744546AbbVie
No Longer Available
不适用
Expanded Access to ABBV-787Acute Myeloid LeukemiaNCT06439966AbbVie
Available
不适用
Expanded Access to Telisotuzumab AdizutecanNCT05982873AbbVie